Introduction
The chances have never been better to survive a cancer for a long time or be completely cured of it. More than 3.2 million peo-study where increased mortality concurred with higher fatigue levels, which was, however, related to cardiovascular disease and not cancer [5] .
Etiology
Systemic inflammation with elevated proinflammatory cytokines has long been proposed as a cause for fatigue. This is supported by the observation that specific genetic polymorphism in the regulatory pathways of immune systems, i.e. TNF-α, IL-1β, IL-4 and IL-6 genes, is associated with elevated CRF [6] . In accordance with this finding, measurements of systemic inflammation relate to fatigue levels [7] .
Another hypothesized mechanism of CRF is a dysregulation in the hypothalamic-pituitary-adrenal axis. A study on alterations in the diurnal cortisol patterns revealed that elevated evening cortisol levels and higher overall cortisol secretion were associated with increased physical fatigue, but not with the cognitive and affective dimension [8] . This finding also indicates that physical and mental fatigue might be separate phenomena with potentially different pathogeneses.
Onset of fatigue often begins with the initiation of classical chemotherapy. Recent studies on new targeted therapies also demonstrate the potential risk of developing fatigue when patients were treated with immune checkpoint inhibition targeting CTLA-4 [9] , tyrosine kinase inhibitors, such as sunitinib [10] , and other vascular endothelial growth factor receptor tyrosine kinase inhibitors [11] or CDK4/6 inhibitors [12] .
Diagnosis
Several questionnaires are on hand to facilitate detection and evaluation, e.g. the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. Clinicians should be attentive to symptoms related to CRF since they tend to be ignored, poorly managed and seldom reported by patients, because they assume that these symptoms are normal and temporary reactions to cancer treatment. Additionally, to ensure a routine screening for these and other symptoms, computerized adaptive testing can be used [13] . To overcome subjective measures with self-reporting questionnaires the evaluation of CRF can also be supplemented by recognizing step count and sleep times with smart bracelets to predict physical fatigue [14] .
Treatment
Cognitive behavioral intervention could include learning about the benefits of exercise, relaxation and good sleep routines. Education may have effects on reducing the intensity of fatigue amongst patients with non-advanced cancer [15] . Patients benefit from intervention if it starts simultaneously with cancer-specific therapy, as shown with breast cancer patients who underwent radiation therapy and were subjected to combined multiple cognitive-behavioral components and hypnosis [16] .
Distress and insomnia are frequently found in cancer patients and associated with fatigue [17] . Cognitive behavior therapy led to remission of insomnia in about half of the patients, whereas almost a fifth reported relief from fatigue [18] . Sleep quality could also be improved with relaxing acupressure, leading to reduced symptoms of fatigue [19] . Methylprednisolone has been shown to reduce fatigue in patients with advanced cancer but it should be used with care in long-term treatment [20] . Apart from this drug no other has yet been found to be effective in randomized controlled trials.
Dietary supplements are often used despite a lack of evidence from placebo-controlled trials. However, 1 such trial revealed Wisconsin ginseng to be more effective than placebo in reducing fatigue, purportedly due to effects on systemic inflammation and modulation of cortisol levels [21] .
Physical exercise has been shown to be effective in reducing fatigue irrespective of the time point when exercise started [22] . There seems to be no clear dose effect in exercise intervention regarding improvement of fatigue, with 1 study showing comparable effects of moderate as well as a high-intensity exercise [23] . Yoga, for example, constitutes an effective training when performed for 90 min twice per week and was accompanied by lower levels of proinflammatory cytokines [24] .
Although exercise intervention is potent in lowering physical fatigue, it is less effective in treating affective and cognitive fatigue. A 12-week resistance exercise program during adjuvant radiotherapy [25] or chemotherapy [26] of breast cancer patients was an efficacious strategy for reducing total fatigue, particularly physical fatigue.
Since the effects of exercise intervention diminish with time, efforts are made to achieve a sustainable impact in cancer survivors. In German rehabilitation centers, group-based training is limited to a 3-6-week period. When supplemented by 2 additional 1-week inpatient stays after 4 and 8 months and based on individual exercise programs, positive effects can be prolonged to at least 2 years after initiation of intervention [27] .
Cognitive Dysfunction

Epidemiology
Cognitive dysfunction (CD) in the form of concentration and memory impairment is detected in up to 75% of cancer patients. In particular women after breast cancer are affected by CD in about 30% of the cases. A deterioration of cognitive function is often observed after chemotherapy, and the function even remains reduced in the long term in 15-45% of the patients [28] .
Etiology
In general, CD is assumed to be related to the respective antitumor treatment. Between 1995 and 2012, 53 studies were published that suggest an effect of chemotherapy on CD [29] . However, CD seems to be a complex problem in cancer patients and cannot be simply reduced to the chemotherapy performed. It was demonstrated that factors such as depression, anxiety and fatigue also play a role [30] [31] [32] . Moreover, a subjectively perceived poor quality of life also appears to have a negative impact on cognitive function [33] . In particular, the effects of a post-traumatic stress situation at the diagnosis of cancer on a person's mental health differ individually, and can also cause impairment of the cognitive performance [34] . Moreover, thorough patient education concerning a possible cytotoxic agents-induced CD is likely to favor the development of subjectively perceived limitations [35] .
Diagnosis
A systematic screening of cognitive disorders has not yet been established as neuropsychological test batteries require special knowledge and are time consuming. For a simplified diagnosis of CD, the d2 test, the CogPack ® and the NeuroCog FX-Test ® can be used [36] . The Mini Mental Test is not suitable for diagnosing CD in cancer patients since it can only confirm or exclude dementia.
Treatment
There is still no medication to treat CD [37] . So far, only low efficacy has been established in psycho-oncological therapy approaches [38] . Only computer-assisted therapeutic interventions have proven to be beneficial [39] [40] [41] . Some studies point out the effectiveness of yoga, meditation, Qi Gong and MBSR (mindfulness-based stress reduction) [42] [43] [44] [45] . Physical activities may also improve or even prevent CD [46, 47] .
Chemotherapy-Induced Polyneuropathy
Epidemiology Chemotherapy-induced polyneuropathy (CIPN) continues to be of high clinical relevance as it not only significantly impairs the quality of life after chemotherapy but also the feasibility of oncological therapies. 60-90% of all patients who have received a potential neurotoxic therapy complain of numbness, sensory alterations, or even impairment in their everyday lives and their work [48] . The introduction of new drugs has not led to any decline in CIPN. Instead, modern signal pathway therapies (e.g. sunitinib), proteasome inhibitors (bortezomib, thalidomide) or eribulin can also cause a toxic polyneuropathy.
Etiology
Insights from recent research indicate a more differentiated pathogenesis. The neuron can be damaged along the whole length from the cell body to the free nerve endings. In addition to the previous distinction between myelin sheath and axonal injury, mitochondrial damage as well as oxidative stress or damage to the nerve blood vessels are currently being discussed [49] . There are as yet no concrete treatment options arising from this knowledge.
Diagnosis
In addition to the extent of troublesome pain and sensation alteration (grade I), special attention should be paid to the diagnosis of functional deficits (grade II) without or with impairments in everyday life (grade III) [50] . The latter can be diagnosed clinically with simple functional tests (picking up coins or clamps, turning pages, Romberg's test, tandem stand, tandem walk, standing on 1 leg). Early warning signs are a failure of the muscle reflexes and a deterioration of the vibration sense (as part of deep sensation) [51] .
Sensation deficits should always be examined by testing the superficial sensitivity and vibration sense, as the deficits are often more extensive than the patient specifies.
Treatment
Unfortunately, there are still no convincing approaches for drug treatment, either in prevention or the therapy of CIPN. In particular, B vitamins should be dispensed with since neither the Cochrane Review nor ASCO Guideline could find any benefit. On the contrary, potentially neurotoxic effects have been described. Duloxetine, in Germany approved only for the treatment of diabetic polyneuropathy, can be moderately recommended [52] .
Neuropathic pain should always be treated according to guidelines with the use of antiepileptics, antidepressants and opioids. NSAIDs are not effective. Various topical products are available but sufficient clinical data and experience for their effectiveness are missing. On the other hand, there are good data on the preventive and therapeutic effect of sensorimotor training (SMT). When carried out on a preventive basis during chemotherapy, SMT improved balance and stumbling reflexes in the course of chemotherapy in comparison to the control group [53] . Conducted later, after the formation of a CIPN, SMT improves symptoms and quality of life [54] . A randomized study of magnetic field therapy demonstrated a significant improvement in nervous conduction velocity and a subjective improvement in the severity of neurotoxicity in a small patient group after 3 months [55] . Another promising approach is vibration training on plates or with dumbbells [56] . However, the exact implementation is still being explored in ongoing studies. Often low purely relaxing frequencies are used, from which no neuroregenerative effect is to be expected.
In rehabilitation, these findings are individually implemented, e.g. gripping exercises for hands and toes, balance training in combination with equipment training, and strength training for the hands with therapy plasticine [57] . It is important that the individuals perform the training exactly at their threshold for symptoms. Overall, active occupational and physiotherapeutic treatments, e.g. QiGong, TaiChi and Yoga, including balance exercises, are seen to be more effective than passive therapies, e.g. hydrogalvanic baths. With appropriate training, long-term continuous improvements are to be expected. The possibilities for a stepwise reintegration into working life should be used during which the professional requirements can be trained in a gradual process. In the course of inpatient or ambulatory rehabilitation, resources enabling participation in working life can be prescribed, which include aids and appliances for the workplace and qualification measures [58] .
Cardiotoxicity
Epidemiology
The incidence of treatment-induced progressive decline in left ventricular function (LVF) to overt heart failure (HF) is a major, but still under-recognized, cause of mortality in long-term cancer survivors. Formerly, long-term cardiotoxicity used to be relevant in particular in pediatric oncology since almost 80% of children live more than 15 years after cancer diagnosis, and cardiotoxic complications have been reported 30 years after treatment in 8.3% of survivors [59, 60] . Cardiovascular disease is the second leading cause of long-term morbidity and mortality among cancer survivors. In early stage, receptor-positive breast cancer it is already the most common cause of death for women [61, 62] .
Etiology
Conventional chemotherapy and targeted therapy are associated with an increased risk of cardiac damage, including left ventricular dysfunction (LVD) and HF, treatment-induced hypertension (e.g. bevacizumab), vasospastic and thromboembolic ischemia (e.g. antimetabolites and hormonal therapy), as well as cardiac arrhythmias (e.g. taxanes) and may be life threatening during the course of disease. In particular, chemotherapeutic agents such as anthracyclines, antimetabolites and cyclophosphamide may cause permanent myocardial cell injury, leading to acute or chronic LVD and HF. Anthracycline-induced cardiotoxicity is mostly dose dependent and for doxorubicin, cardiac complications have been described in 4-36% of patients at cumulative doses of > 500 mg/m 2 [63] . The mechanism of anthracycline-induced cardiac injury remains to be fully understood. Structural cardiomyocyte damage and cell death are mediated in part by reactive oxygen species (ROS) generated in iron-dependent chemical reactions and disturbances in DNA topoisomerase 2-β metabolism.
While in previous years doxorubicin and chest/mediastinal radiation were the most frequent causes of LVD or HF, numerous other potential cardiotoxic medications are routinely administered today such as monoclonal antibodies (e.g. trastuzumab), anti-microtubule substances (e.g. taxanes) or small molecules (e.g. sunitinib).
LVD/HF associated with targeted therapies has been most extensively studied in breast cancer patients treated with trastuzumab. It has been suggested that cardiac dysfunction may be a direct consequence of Erb2 inhibition in cardiomyocytes. In contrast to anthracycline-induced cardiomyopathy, trastuzumab-induced cardiomyopathy is potentially reversible and after treatment cessation cardiac function will not further deteriorate. Treatment combinations such as anthracyclines and trastuzumab often employed in breast cancer therapy may enhance cardiotoxicity [64] . Taxane-induced cardiotoxicity mainly comprises (sub)acute rhythm problems such as bradycardias or (supra)ventricular arrhythmias and is observed in 0.5% of patients. Taxanes as monotherapy do not induce heart failure, but, in combination therapy, anthracycline elimination is reduced so that the plasma levels of anthracycline increase [65] . Cardiac events have been reported during treatment with small molecules in up to 34% of patients, with the left ventricular ejection fraction (LVEF) being significantly reduced in 12% of cases [66] .
Diagnosis
Echocardiography is the most commonly used technique to monitor cardiac function during and after therapy. Biomarkers of cardiac injury have also been shown to identify patients at risk for cardiotoxicity, but their value in routine patient care is still controversially discussed. However, the finding of a significantly raised B-type natriuretic peptide (BNP) or its precursor (NT-proBNP) provides evidence of HF with high sensitivity [67, 68] . Better monitoring and more sensitive recognition of cardiac function using strain echocardiography, Doppler myocardial imaging (DMI) and cardiac MRI are in development and may yield progressive utility in predicting subsequent cardiotoxicity.
Treatment
All cancer survivors at risk should routinely undergo a cardiovascular screening during therapy and follow-up. Rehabilitation interventions, including evidence-based recommendations for nutrition and physical activity as well as smoking cessation for primary prevention of cardiovascular disease should be initiated early. Several studies provide growing evidence of protective effects of such interventions on long-term cardiovascular health [62] . In addition, all patients should be assessed for co-existing morbidities such as diabetes mellitus and arterial hypertension and, if present, medical treatment should be optimized.
Management of patients who have symptoms of overt cardiac toxicity represents a great challenge since no oncology-specific guidelines for cardiovascular toxicities so far exist. Therefore, medical treatment recommendations are usually the same as for general HF patients and comprise angiotensin converting enzyme (ACE)/ angiotensin (AT) inhibitors, β blockers and diuretics [69] .
Patients with LVD or manifest HF may also benefit from a multidisciplinary biopsychosocial rehabilitation program, in particular psychological support and exercise-based interventions. Numerous studies in patients with heart disease have consistently shown that moderate (but also high-intensity interval) aerobic exercising and resistance training improves exercise capacity (VO 2peak ) with concomitant improvement of LVEF, physical fitness parameters, muscle strength, health-related quality of life and depressive symptoms [70] .
Lymphedema
Epidemiology
Cancer-related lymphedema (LE) is a debilitating condition of the lymphatic system with long-term adverse impact on quality of life, health, physical function, psychosocial wellbeing, and employment, and is characterized by a continuous need for medical treatment. In breast cancer patients the incidence of arm LE seemed to increase up to 2 years after surgery. It was about 4 times higher in women who had an axillary lymph node dissection (ALND) (19.9%) than that in those who had sentinel node biopsy (5.6%) [71] . In women with gynecological cancer and inguinal lymph node dissection about 50% developed lower-limb LE within 2 years after surgery [72] . 60% of LE cases were persistent and 40% were transient [73] .
Etiology LE is a chronic, progressive swelling caused by a disruption of lymph transport. In cancer survivors secondary LE can develop after radical operative dissection (e.g. axillary or retroperitoneal nodal sampling), irradiation, or from repeated lymphangitis with lymphangiosclerosis [74, 75] . Well-defined risk factors for developing LE in cancer patients include extensive surgery (i.e. ALND), greater number of lymph nodes dissected, mastectomy, regional lymph node irradiation, infection, obesity, older age at diagnosis and low physical activity levels [71, 73, [76] [77] [78] .
Diagnosis
In most patients diagnosis of LE can be readily determined by the clinical history and physical examination (inspection, palpation). If the diagnosis of LE is unclear or in patients with multiple comorbidities, special morphological or functional diagnostic may be necessary, e.g. ultrasonography, duplex-Doppler studies for examining the venous system, magnetic resonance imaging, isotope lymphography or fluorescent microlymphangiography. An assessment of limb volume should be made before, during and after treatment [74, 75] . Non-measurable LE should be documented by photography.
Treatment
Patients after axillary surgery are often advised to avoid blood pressure measurements, skin punctures (e.g. ipsilateral blood draws or injections) and air travel to prevent potential infection. Most of these recommendations, although found in National guidelines [74, 79] , yet remain unsustained by high-level scientific evidence [78] . A recent large prospective study [80] showed no significant association between these potential risk factors and the subsequent risk of LE. Instead, patients should be advised to maintain an active life style since inactivity even appears to exacerbate LE [81] . Physical exercise and resistance training after breast cancer treatment does not increase the risk of developing LE provided that symptoms are monitored and treated immediately if they occur [82] [83] [84] [85] [86] . A positive effect on the lymphatic backflow may be achieved specifically through dynamic intermittent activities such as moderate strength training, Nordic walking and water therapy [81, 87, 88] . In a randomized controlled trial involving 141 breast cancer survivors with stable LE of the arm, slowly progressive resistance training undertaken with a compression garment is actually protective against LE flair-ups [89] , and there is no association between performing heavy resistance training and the development of breast cancer-related LE [90, 91] . Also, dragon boat paddling with vigorous, repetitive upper body exercise is safe for women recovering from conventional breast cancer therapies and does not initiate LE or exacerbate preexisting LE [92, 93] .
There is no evidence for prophylactic manual lymphatic drainage (MLD) (except in the first few days after surgery), compression therapy or combined physical therapy (CPT) [74] . In the absence of evidence, after gynecological surgery, it has been recommended that those patients at risk for lower extremity LE wear a well-fitting circular-knit compression garment during exercise.
Basic treatment is CPT, although the efficacy of CPT and different combinations of its constituents are not well established [74, 75, [94] [95] [96] [97] [98] . It involves a 2-stage treatment program. In the first phase, swelling reduction is obtained by MLD, compression therapy, typically applied with multi-layered bandage wrapping, and motion exercises of the extremities, especially combined with external limb compression. Thereafter, results are conserved and optimized by compression with a low-stretch elastic stocking or sleeve, skin care, continued 'remedial' exercise, and repeated MLD as needed.
MLD without compression therapy does not appear to be of benefit. Kinesio ® Tex taping could be helpful and does not harm, but there is no study showing significant difference in limb size [98, 99] . Microsurgical lymphatic reconstruction or bypass techniques including lymph node transfer, lymphatico-lymphatic bypass and lymphaticovenous anastomoses could also be effective and applied after failure of all conservative treatments [74, 98] .
Conclusion
Rehabilitation is an integral part of patient care in oncology and provides an ideal opportunity for focusing on treatment-related long-term consequences. Rehabilitation is offered in different settings in European countries. In Germany, patients affected have the opportunity to undertake a rehabilitation not only immediately but also 1 and 2 years after completion of cancer-specific primary therapy; if complaints persist this can be repeated every 4 years. Information, education and motivation for life style changes are essential treatment elements in medical rehabilitation and are supplemented by further evidence-based interventions.
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